Neurosense Therapeutics Ltd (NRSN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Neurosense Therapeutics Ltd stock (NRSN) is currently trading at $0.73. Analyst consensus price target for NRSN is $11.50. WallStSmart rates NRSN as Sell.
- NRSN PE ratio analysis and historical PE chart
- NRSN PS ratio (Price-to-Sales) history and trend
- NRSN intrinsic value — DCF, Graham Number, EPV models
- NRSN stock price prediction 2025 2026 2027 2028 2029 2030
- NRSN fair value vs current price
- NRSN insider transactions and insider buying
- Is NRSN undervalued or overvalued?
- Neurosense Therapeutics Ltd financial analysis — revenue, earnings, cash flow
- NRSN Piotroski F-Score and Altman Z-Score
- NRSN analyst price target and Smart Rating
Neurosense Therapeutics
📊 No data available
Try selecting a different time range
Smart Analysis
Neurosense Therapeutics Ltd (NRSN) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Neurosense Therapeutics Ltd (NRSN) Key Strengths (0)
Supporting Valuation Data
Neurosense Therapeutics Ltd (NRSN) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 12.8x book value
Very low institutional interest at 1.72%
Micro-cap company with very limited liquidity and high volatility
Neurosense Therapeutics Ltd (NRSN) Detailed Analysis Report
Overall Assessment
This company scores 6/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 0 register as strengths (avg 0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Institutional Own.. Some valuation metrics including Price/Book (12.82) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -2478.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -2478.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NRSN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Neurosense Therapeutics Ltd (NRSN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Neurosense Therapeutics Ltd operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -2,000, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.56, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Neurosense Therapeutics Ltd.
Bottom Line
Neurosense Therapeutics Ltd offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Neurosense Therapeutics Ltd(NRSN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm focused on developing groundbreaking therapies for neurodegenerative diseases, with a primary emphasis on Parkinson's disease. Through its proprietary development platform, the company is actively advancing several therapeutic candidates in critical clinical trials, highlighting its dedication to addressing significant unmet needs in neurology. Led by an experienced management team and supported by strategic partnerships, Neurosense is well-positioned to provide innovative treatment solutions that enhance patient quality of life while establishing a strong foothold in the biopharmaceutical industry.